covid_cell_1_1

Pharmafile.com’s weekly COVID-19 news round-up

pharmafile | August 12, 2020 | News story | Research and Development COVID-19, coronavirus, covid news 

The coronavirus news this week once again focuses on vaccines, as AstraZeneca signed its first deal in China to produce and deliver its vaccine candidate, while the US will pay Johnson and Johnson more than $1 billion to create 100 million doses of a vaccine. In terms of people being willing to take a vaccine, 35% of Americans say they have no plans to be inoculated against the virus, according to new polling.

In hydroxychloroquine news, researchers at the University of Oxford have said that the drug could be beneficial to COVID-19 patients, despite a general lack of evidence for its effectiveness. 

 1. AstraZeneca seals manufacturing deal to deliver COVID-19 vaccine in China – Published on 07/08/2020

Advertisement

AstraZeneca has signed its first deal in China to produce and deliver its vaccine candidate against COVID-19 in the country, partnering up with manufacturing firm Shenzhen Kangtai Biological Products.

2. Researchers at the University of Oxford have said hydroxychloroquine could still be a viable COVID-19 treatmentPublished on 07/08/2020

Researchers at the University of Oxford have said that hydroxychloroquine could be beneficial to COVID-19 patients, despite a general lack of evidence for its effectiveness. 

3. US to pay Johnson and Johnson $1 billion for COVID-19 vaccinePublished on 06/08/2020

The US will pay Johnson and Johnson more than $1 billion to create 100 million doses of COVID-19 vaccine.

4. Over a third of Americans say they won’t take a coronavirus vaccinePublished 10/08/2020

35% of Americans say they have no plans to take a COVID-19 vaccine, according to new polling.

5. Early promise from Novavax’s vaccine candidate for COVID-19Published 07/08/2020

New Phase 1/2 on Novavax’s COVID-19 vaccine candidate NVX‑CoV2373 has shown that the therapy generated “robust antibody responses” when used with or without the company’s Matrix‑M adjuvant.

Related Content

covid_cell

COVID-19 vaccine eligibility creates challenges for UK pharmacies

Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

Vaccine image

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …

The Gateway to Local Adoption Series

Latest content